ITMCTR2200006839尚未招募1 期
Randomized double-blind placebo-controlled clinical observation and central mechanism of acupoint catgut embedding in the treatment of chronic spontaneous urticaria
Guang 'anmen Hospital0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 60（—）
- 性别
- All
入选标准
- •(1)Age between 18 and 60, regardless of gender;(2)Meet the diagnostic criteria of chronic spontaneous urticaria;(3)Despite the use of H1 antihistamines, wind masses and pruritus were present for at least 6 weeks prior to enrollment; At least once a day, mainly wind mass and pruritus, without serious systemic symptoms.(4)7-day urticaria activity score (UAS)=16 points, weekly pruritus score = 8 points;(5)No history of catgut embedding;(6)Sign informed consent, volunteer to participate in this study.
排除标准
- •(1) Clear cause of chronic urticaria (such as physical urticaria); (2)Glucocorticoid, hydroxychloroquine, methotrexate, cyclosporine, cyclophosphamide, or intravenous immunoglobulin for any indication (daily, or more than 3 consecutive other days) received during the first 30 days of enrollment; (3)Received any H2 antihistamine, leukotriene receptor antagonist, omalizumab and other biological agents 7 days before screening and 14 days before randomization;(4) Three days before screening, H1 antihistamines exceeded the permitted dose; (5)Complicated with serious cardiovascular and cerebrovascular diseases, diabetes, abnormal bone metabolism and other diseases, or liver and kidney diseases, hematopoietic system and other serious primary diseases; Patients with systemic lupus erythematosus and other serious autoimmune diseases; (6) Diseases other than chronic urticaria with symptoms of urticaria or angioedema, such as urticaria vasculitis, Erythema multiform, cutaneous mastocytosis (pigmentary urticaria) and hereditary or acquired angioedema (e.g., due to deficiency of C1 inhibitor);(7)Skin diseases related to chronic pruritus (e.g., atopic dermatitis, bullous pemphigus, herpetic dermatitis, pruritus in old age, etc.) that may affect the evaluation and treatment of the study; (8) People allergic to buried wire materials; (9)Women with fertility needs, pregnancy and lactation during the study period;(10) Contraindicated mri patients;(11)Participating in or participating in other clinical trials within the last 3 months; (12)Used psychotropic drugs within the past month.
研究者
相似试验
尚未招募
1 期
Randomized double-blind placebo-controlled clinical trial of Jiangtang Xiaozhi decoction for the management of metabolic-associated fatty liver diseasemetabolic-dysfunction-associated fatty liver diseaseITMCTR2024000161Xiyuan Hospital, China Academy of Chinese Medical Sciences
已完成
4 期
Medical management of compartment syndromeCTRI/2012/11/003089Christian Medical College Vellore40
进行中（未招募）
1 期
The effect of EA-230 on the immuneresponseEUCTR2014-002481-78-NLExponential Biotherapies Inc60
已完成
不适用
Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune response during experimental human endotoxemiaNL-OMON40791Exponential Biotherapies inc.60
尚未招募
2 期
To Investigate the anti-proliferative and anti-cancer potential of Moclobemide (an anti-depression drug) in castration resistant prostate cancer.CTRI/2023/01/048893ICMR-Product Development Centre at AIIMS New Delhi